Cost effectiveness sensitivity

This page is a encyclopedia article. The page identifier is Op_en6838
Moderator:Nobody (see all) Click here to sign up.
Give your opinion to the peer rating of the content of this page. {{ #opasnet_rater: }}
Upload data

The effects of alternative vaccine compositions on the outcomes of the cost-benefit analysis were assessed. Five modifications for PCV10 and one for PCV13 were considered

Conclusion: The assumption about serotype 3 in PCV13 is crucial. In addition, assumptions about the role of 6A in PCV10 is important.

 PCV13adv.inIPD 
   = (IPD under PCv10) - (IPD under PCV13)
   if positive, PCV13 saves IPD compared to PCV10

 price of PCV13 
   =  if PCV10 price set at 20e, what is the matching price for PCV13?

 ICER 
   = incremental cost-effectiveness ratio for PCV10 at price 20e
    (in this table, this value is also average cost per QALY)

 rows:
 [1]  pcv10       
 [2]  pcv10+19A direct effects
 [3]  pcv+6A      
 [4]  pcv10+19A(direct only)+6A
 [5]  pcv10+19A full  
 [6]  pcv10+19Af+6=PCV13-3

 columns:
 [1]  pcv13-3       
 [2]  pcv13

                PCV13adv.inIPD   price of PCV13    ICER
                 --------------   --------------    ---------------
                 PCV13-3  PCV13   PCV13-3  PCV13    PCV13-3   PCV13
                   ---     ---     -----    ---      -----     ----
  pcv10             12     150       18    38         8077     8077
  pcv10+19Ad        -2     134       17    37         7714     7714
  pcv10+6A          50     188       25    55        13590    13590
  pcv10+19Ad+6A     32     169       24    52        12724    12724
  pcv10+19Af       -31     105       15    32         6198     6199
  pcv10+19Af+6A      *     137        *    43            *     9672
                                 (PCV10 price=20)